Exploiting anthracycline scaffold for designing DNA-targeting agents.
Priebe
W
W
M. D. Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA.
Fokt
I
I
Przewloka
T
T
Chaires
J B
JB
Portugal
J
J
Trent
J O
JO
D018943:Anthracyclines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D001483:Base Sequence; D001665:Binding Sites; D020650:Combinatorial Chemistry Techniques; D004247:DNA / Q000737:chemistry* / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D005822:Genetic Vectors; D006801:Humans; D066298:In Vitro Techniques; D007364:Intercalating Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D009154:Mutation; D009690:Nucleic Acid Conformation; D013816:Thermodynamics; D014158:Transcription, Genetic / Q000187:drug effects; D014961:X-Ray Diffraction
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D007364:Intercalating Agents; C104426:WP 631; D004247:DNA; D003630:Daunorubicin